MX2015004806A - Composiciones y metodos para el tratamiento de la enfermedad de parkinson. - Google Patents

Composiciones y metodos para el tratamiento de la enfermedad de parkinson.

Info

Publication number
MX2015004806A
MX2015004806A MX2015004806A MX2015004806A MX2015004806A MX 2015004806 A MX2015004806 A MX 2015004806A MX 2015004806 A MX2015004806 A MX 2015004806A MX 2015004806 A MX2015004806 A MX 2015004806A MX 2015004806 A MX2015004806 A MX 2015004806A
Authority
MX
Mexico
Prior art keywords
parkinson
disease
compositions
treatment
methods
Prior art date
Application number
MX2015004806A
Other languages
English (en)
Inventor
Ruth Perez
Original Assignee
Ruth Perez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruth Perez filed Critical Ruth Perez
Publication of MX2015004806A publication Critical patent/MX2015004806A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método para tratar, aliviar, invertir o retrasar el progreso de al menos un síntoma de la enfermedad de Parkinson en un sujeto en necesidad del mismo, al administrar al sujeto una cantidad efectiva de una composición de 2-amino-2-[2-(4-octilfenil)etil)propano-1,3-diol o un derivado del mismo para tratar al menos un síntoma de la enfermedad de Parkinson.
MX2015004806A 2012-10-19 2013-10-18 Composiciones y metodos para el tratamiento de la enfermedad de parkinson. MX2015004806A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261716313P 2012-10-19 2012-10-19
PCT/US2013/065694 WO2014063057A1 (en) 2012-10-19 2013-10-18 Compositions and methods for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
MX2015004806A true MX2015004806A (es) 2015-11-18

Family

ID=50488788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004806A MX2015004806A (es) 2012-10-19 2013-10-18 Composiciones y metodos para el tratamiento de la enfermedad de parkinson.

Country Status (4)

Country Link
US (1) US10391066B2 (es)
CA (1) CA2888634C (es)
MX (1) MX2015004806A (es)
WO (1) WO2014063057A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2961187A1 (en) * 2014-09-16 2016-03-24 Teva Pharmaceuticals Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172711T1 (de) * 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
US20080221200A1 (en) 2005-09-30 2008-09-11 Malcolm Allison Combination of Organic Compounds
US8673982B2 (en) * 2009-02-24 2014-03-18 Novartis Ag Ceramide-analogous metabolites
WO2012074960A2 (en) * 2010-11-29 2012-06-07 The Ohio State University Research Foundation Fty720-derived anticancer agents

Also Published As

Publication number Publication date
US10391066B2 (en) 2019-08-27
CA2888634C (en) 2019-10-08
WO2014063057A1 (en) 2014-04-24
CA2888634A1 (en) 2014-04-24
US20150290145A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
BR112015022197A2 (pt) tratamento de cataplexia
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX343931B (es) Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2015006720A (es) D-metadona para el tratamiento de sintomas psiquiatricos.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
BR112016016098A2 (pt) Compostos orgânicos
BR112018069174A2 (pt) tratamento de prurido urêmico
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2015004806A (es) Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
BR112022008639A2 (pt) Tratamento de distúrbios do fígado
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
MX358072B (es) Composiciones tópicas que comprenden diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que involucran un aumento del dolor.